A hallmark of Parkinson’s is the presence of abnormal protein clumps, known as Lewy bodies, in the brain. However, some ...

"Furthermore, patients with RLS who were not treated with dopamine agonists tended to be at increased risk of developing ...

Previous applications of TUS were limited, as they were imprecise and too weak to target areas deeper in the brain. Parkinson ...

An acclaimed researcher is an expert at explaining complicated problems. Now she has to confront the most vexing question: ...

The movement disorder is estimated to affect tens of thousands of Americans in a severe enough way to impact their daily life ...

Roche RHHBY announced that it will advance pipeline candidate prasinezumab into phase III development for early-stage Parkinson’s disease. Roche has a licensing agreement with Prothena PRTA for ...

Preclinical data demonstrates that Shape’s engineered AAV5 variant, SHP-DB1, efficiently targets the NHP brain after intravenous injection and ...

Precision medicine holds enormous promise in enhancing treatment efficacy and advancing therapeutic development, leading to more equitable care. However, to realise this promise in all individuals ...

Neurocrine Biosciences Inc on Monday launched its add-on treatment for patients with Parkinson's disease nearly five months after Food and Drug Administration's approval, as the COVID-19 pandemic ...